Cell reprogramming requires efficient delivery of reprogramming transcription factors into the cell nucleus. Here, we compared the robustness and workload of two protein delivery methods that avoid the risk of genomic integration. The first method is based on fusion of the protein of interest to a protein transduction domain (PTD) for delivery across the membranes of target cells. The second method relies on de novo synthesis of the protein of interest inside the target cells utilizing synthetic mRNA (syn-mRNA) as a template. We established a Cre/lox reporter system in three different cell types derived from human (PANC-1, HEK293) and rat (BRIN-BD11) tissues and used Cre recombinase to model a protein of interest. The system allowed constitutive expression of red fluorescence protein (RFP), while green fluorescence protein (GFP) was expressed only after the genomic action of Cre recombinase. The efficiency of protein delivery into cell nuclei was quantified as the frequency of GFP+ cells in the total cell number. The PTD method showed good efficiency only in BRIN-BD11 cells (68%), whereas it failed in PANC-1 and HEK293 cells. By contrast, the syn-mRNA method was highly effective in all three cell types (29-71%). We conclude that using synthetic mRNA is a more robust and less labor-intensive approach than using the PTD-fusion alternative.

Department of Diabetes Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Experimental Medicine Institute for Clinical and Experimental Medicine Prague Czech Republic

See more in PubMed

Haethman TRJ, Nienow AW, McCall MJ, Coopman K, Kara B, Hewitt ChJ. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regen. Med. 2015;10: 49–4. doi: 10.2217/rme.14.73 PubMed DOI

Stadtfeld M, Brennand K, Hochedlinger K. Reprogramming of pancreatic Beta cells into induced pluripotent stem cells. Curr. Biol. 2008;18:890–94. doi: 10.1016/j.cub.2008.05.010 PubMed DOI PMC

Woltjen K, MichaelI P, Mohseni P, Desai R, Mileikovsky M. piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. Nature. 2009;458:766–70. doi: 10.1038/nature07863 PubMed DOI PMC

Stephen SL, Montini E, Sivanandam VG, Al-Dhalimy M, Kestner HA, Finegold M, et al. Chromosomal integration of adenoviral vector DNA in vivo. J. Virol. 2010;84:9987–94. doi: 10.1128/JVI.00751-10 PubMed DOI PMC

Hacein-Bey-Abina S, Kalle CV, Schmidt M, McCormack MP, Wulffraat N, Leboulch P. LMO2-associated clonal T cell croliferation in two patients after gene therapy for SCID-X1. Science. 2003;17:415–19. PubMed

Ho A, Schwarze SR, Mermelstein SJ, Waksman G, Dowdy SF. Synthetic protein transduction domains: enhanced transduction potential in vitro and in vivo. Cancer Res. 2001;61:474–77. PubMed

Wadia JS, Dowdy SF. Protein transduction technology. Nature Current Op. in Biotech. 2002;13:52–6. PubMed

Dohoon K, Chun-Hyung K, Jung-II M, Young-Gie C, Mi-Yoon C, Baek-Soo H, et al. Generation of human induced pluripotent stem cells by direct delivery of reprogramming proteins. Cell Stem Cell. 2009;4:472–76. doi: 10.1016/j.stem.2009.05.005 PubMed DOI PMC

Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–872. doi: 10.1016/j.cell.2007.11.019 PubMed DOI

Sahin U, Kariko K, Tureci O. mRNA-based therapeutics-developing a new class of drugs. Nature Rew. Drug Discovery. 2014;19:1–22. PubMed

Wiehe JM, Ponsaerts P, Rojewski MT, Homann JM, Greiner J, Kronawitter D, et al. mRNA-mediated gene delivery into human progenitor cells promotes highly efficient protein expression. J. Cell. Mol. Med. 2007;11:521–30. doi: 10.1111/j.1582-4934.2007.00038.x PubMed DOI PMC

Warren L, Manos PD, Ahfeldt T, Loh Y, Li H, Daley Q, et al. Highly efficient reprogramming to pluripotency and directed differentiation of human cells using synthetic modified mRNA. Cell Stem Cell. 2010;7:618–30. doi: 10.1016/j.stem.2010.08.012 PubMed DOI PMC

Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, et al. A comparison of non-integrating reprogramming methods. Nat. Biotechnol. 2015;33:55–60. PubMed PMC

Koblas T, Leontovyc I, Loukotova S, Kosinova L, Saudek F. Reprogramming of pancreatic exocrine cells AR42J into insulin-producing cells using mRNAs for Pdx1, Ngn3, and MafA transcription factors. Molecular therapy-nucleic acids. 2016. May 17;5:e320 doi: 10.1038/mtna.2016.33 PubMed DOI PMC

Lieber M, Mazzetta J, Nelson-Rees W, Kaplan M, Todaro G. Establishment of a continuous tumor-cell line (PANC-1) from a human carcinoma of the exocrine pancreas. Int. J. Cancer. 1975;15:741–47. PubMed

Zhang T, Wang H, Saunee NA, Breslin MB, Lan MS. Insulinoma-associated antigen-1 zinc-finger transcription factor promotes pancreatic duct cell trans-differentiation. Endocrinology. 2010;151:2030–39. doi: 10.1210/en.2009-1224 PubMed DOI PMC

Mcclenaghan NH, Barnett CR, Ah-Sing E, Abdel-Wahab YHA, O´Harte FPM, Yoon T, et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes. 1996;45:1132–40. PubMed

Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 1977;36:59–2. doi: 10.1099/0022-1317-36-1-59 PubMed DOI

Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cell by human adenoviruses and the origin of HEK 293 cells. FASEB J. 2002;16: 869–71. doi: 10.1096/fj.01-0995fje PubMed DOI

Casademunt E, Martinelle K, Jernberg M, Winge S, Tiemeyer M, Biesert L. et al. The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics. Eur. J. Haematol. 2012;89:165–76. doi: 10.1111/j.1600-0609.2012.01804.x PubMed DOI PMC

Nagy A. Cre recombinase: The universal reagent for genome tailoring. Genesis. 2000;26:99–109. PubMed

Kaczmarczyk SJ, Green JE. A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression. Nucleic Acids Res. 2001;29:1–13. PubMed PMC

Kaczmarczyk SJ, Sitaraman K, Young HA, Hughes SH, Chatterjee DK. Protein delivery using engineered virus-like particles. PNAS. 2011;108:16998–7003. doi: 10.1073/pnas.1101874108 PubMed DOI PMC

Kim JH, Lee S, Li L, Park H, Park J, Lee KY, et al. High cleavage efficiency of a 2A peptide derived from porcine teschovirus-1 in human cell lines, zebrafish and mice. PLoS ONE. 2011. April 6;4:e18556. PubMed PMC

Bach H, Mazor Y, Shaky S, Berdichevsky ASY, Gutnick DL, Benhar I. Escherichia colimaltose-binding protein as a molecular chaperone for recombinant intracellular cytoplasmic single-chain antibodies. J. Mol. Biol. 2001;312: 79–93. doi: 10.1006/jmbi.2001.4914 PubMed DOI

Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 2004;10:310–5. doi: 10.1038/nm996 PubMed DOI

Horak ChE, Mahajan MC, Luscombe NM, Gerstein M, Weissman SM, Snyder M. GATA-1 binding sites mapped in the β-globin locus by using mammalian chIp-chip analysis. PNAS. 2002;99: 2924–29. doi: 10.1073/pnas.052706999 PubMed DOI PMC

Raran-Kurussi S, Waugh DS. The ability to enhance the solubility of its fusion partners is an intrinsic property of maltose-binding protein but their folding is spontaneous or chaperone-mediated. PLoS ONE. 2012. November 7;11:e49589 doi: 10.1371/journal.pone.0049589 PubMed DOI PMC

Shaw PA, Catchpole IR, Goddard CA, Colledge WH. Comparison of protein transduction domains in mediating cell delivery of a secreted CRE protein. Biochemistry. 2008;47:1157–66. doi: 10.1021/bi701542p PubMed DOI

Will E, Klump H, Heffner N, Schwieger M, Schiedlmeier B, Ostertag W, et al. Unmodified Cre recombinase crosses the membrane. Nucleic Acids Res. 2002;30:472–76. PubMed PMC

Barber GN, Host defense, viruses and apoptosis. Cell Death Differ. 2001;8:113–26. doi: 10.1038/sj.cdd.4400823 PubMed DOI

Kormann MSD, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, et al. Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 2011;29:154–157. doi: 10.1038/nbt.1733 PubMed DOI

Kariko K, Muramatsu H, Ludwig J, Weissman D. Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Research. 2011. September 39;21:e142 doi: 10.1093/nar/gkr695 PubMed DOI PMC